BioSpace

In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease trials happening abroad and how the FAIR Act’s accelerated, harmonized reviews could help the U.S. keep pace while getting lifesaving studies to patients faster.
Host
⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests
Max Bronstein, CEO, Aviva Strategies
Teresa Barnes, Chief Executive Warrior, PF Warriors
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.

In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of Global Clinical Development. We examine radioligand therapy’s accelerating momentum and how its diagnostic and therapeutic reach could potentially reshape care for more than 14 million patients worldwide.

We also discuss Curium's push to expand US capacity and scale up at pace, and critically what success could mean for patients with cancer in the years ahead.

This episode is presented in partnership with Curium.

Host
Jennifer Smith-Parker, Director of Insights, BioSpace

Guests
Mike Patterson, CEO North America, Curium
Sabine Brookman-May, VP and Head of Global Clinical Development, Curium

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Novo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to turn things around; Viking Therapeutics and Roche report positive results for their weight loss assets; Ultragenyx snags FDA approval for its Sanfilippo syndrome gene therapy; IPOs keep on coming.

In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and Wesley Jackson, chief science officer at Valitor. We talk about the eye condition call wet age-related macular degeneration (AMD), the limits of anti‑VEGF therapy and the push for true durability to change a patient’s life.

Host
Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests
Philip Jacob Rosenfeld, Professor of Ophthalmology, University of Miami Health System, Bascom Palmer Eye Institute
Wesley Jackson, Chief Science Officer, Valitor  

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.